Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Dyslipidaemia

Cardiovascular prevention—end of the road for niacin?

Nature Reviews Endocrinology volume 10, pages 646–647 (2014)Cite this article

Subjects

The recently published HPS2–THRIVE study has shown that the addition of extended release niacin to statin therapy in patients with well-controlled levels of LDL cholesterol does not reduce the risk of cardiovascular events and might even increase harm. Consequently, the use of niacin to increase levels of HDL cholesterol is not recommended.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Biotransformation of niacin.

References

  1. Fruchart, J. C. et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc. Diabetol. 13, 26 (2014).

    Article  Google Scholar 

  2. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2009).

  3. Boekholdt, S. M. et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 128, 1504–1512 (2013).

    Article  CAS  Google Scholar 

  4. Canner, P. L. et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245–1255 (1986).

    Article  CAS  Google Scholar 

  5. HPS2–THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371, 203–212 (2014).

  6. AIM–HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255–2267 (2011).

  7. Ishii, M. et al. CRTH2 is a critical regulator of neutrophil migration and resistance to polymicrobial sepsis. J. Immunol. 188, 5655–5664 (2012).

    Article  CAS  Google Scholar 

  8. Rader, D. J. & Tall, A. R. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat. Med. 18, 1344–1346 (2012).

    Article  CAS  Google Scholar 

  9. Lukasova, M., Malaval, C., Gille, A., Kero, J. & Offermanns, S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J. Clin. Invest. 121, 1163–1173 (2011).

    Article  CAS  Google Scholar 

  10. Yoshino, J., Mills, K. F., Yoon, M. J. & Imai, S. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528–536 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 11–125 Smilow Centre for Translational Research, 3400 Civic Centre Blvd, Philadelphia, 19104, PA, USA

    Sony Tuteja

  2. Department of Genetics, Perelman School of Medicine, University of Pennsylvania, 11–125 Smilow Centre for Translational Research, 3400 Civic Centre Blvd, Philadelphia, 19104, PA, USA

    Daniel J. Rader

Authors
  1. Sony Tuteja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel J. Rader
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Rader.

Ethics declarations

Competing interests

D.J.R has been a consultant for Merck and Eli Lilly. S.T. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tuteja, S., Rader, D. Cardiovascular prevention—end of the road for niacin?. Nat Rev Endocrinol 10, 646–647 (2014). https://doi.org/10.1038/nrendo.2014.159

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2014.159

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing